Connection

Adviye Ergul to Endothelin Receptor Antagonists

This is a "connection" page, showing publications Adviye Ergul has written about Endothelin Receptor Antagonists.
Connection Strength

1.906
  1. Lipopolysaccharide-induced necroptosis of brain microvascular endothelial cells can be prevented by inhibition of endothelin receptors. Physiol Res. 2018 06 27; 67(Suppl 1):S227-S236.
    View in: PubMed
    Score: 0.596
  2. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control. Life Sci. 2014 Nov 24; 118(2):268-73.
    View in: PubMed
    Score: 0.438
  3. Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Can J Physiol Pharmacol. 2010 Jun; 88(6):616-21.
    View in: PubMed
    Score: 0.341
  4. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Pharmacotherapy. 2002 Jan; 22(1):54-65.
    View in: PubMed
    Score: 0.190
  5. Potential role of endothelin receptor antagonists in the setting of cardiopulmonary bypass: relevance to myocardial performance. Heart Fail Rev. 2001 Dec; 6(4):287-94.
    View in: PubMed
    Score: 0.189
  6. Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J Pharmacol Exp Ther. 2011 Apr; 337(1):9-15.
    View in: PubMed
    Score: 0.089
  7. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol. 2006 Feb 17; 5:3.
    View in: PubMed
    Score: 0.063
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.